公开(公告)号：EP1833832A1

公开(公告)日：2007-09-19

申请号：EP06847011.1

申请日：2006-01-02

申请人： GPC Biotech AG

发明人： MÜLLER, Stefan ,  SCHWAB, Wilfried ,  KLEBL, Bert ,  HAFENBRADL, Doris ,  HOPPE, Edmund ,  HORVATH, Zoltán ,  KERI, György ,  VARGA, Zoltán ,  ÖRFI, László ,  MAROSFALVI, Jenö ,  MÜLLER, Gerhard

IPC分类号： C07D471/04 ,  A61K31/4375 ,  A61P7/02 ,  A61P9/00 ,  A61P11/06 ,  A61P19/10 ,  A61P15/10 ,  A61P27/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00

CPC分类号： C07D471/04

摘要： The present invention relates to compounds having a naphthyridine scaffold, and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these naphthyridine derivatives together with pharmaceutically acceptable carrier, excipient and/or diluents. Said naphthyridine compounds have been identified as inhibitors of the protein kinase ROCK2, also known as Rho-kinase, and are useful for the treatment of cancers (tumor growth and metastases), erectile dysfunction, cardiovascular diseases, hypertension, angina pectoris, cerebral ischaemia, cerebral vasospasm, myocardial ischaemia, coronary vasospasm, heart failure, myocardial hypertrophy, atherosclerosis, restenosis, spinal cord injuries, neuronal degeneration, thrombotic disorders, asthma, glaucoma, inflammation, anti-viral diseases (e.g. HIV), and osteoporosis.